Esperion offers another upbeat cut of pivotal cholesterol data for their combo, bumps back readout for key safety study
Over the past few months Esperion $ESPR has been gradually digging out of the hole it found itself in after a small imbalance of deaths …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
